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SCIENTIFIC OPINION 
Scientific Opinion on Flavouring Group Evaluation 98 (FGE.98): 
Consideration of three ring-unsaturated delta-lactones)1 
EFSA Panel on Food Contact Materials, Enzymes, Flavourings and 
Processing Aids (CEF)2, 3 
European Food Safety Authority (EFSA), Parma, Italy 
ABSTRACT 
The Panel on Food Contact Materials, Enzymes, Flavourings and Processing Aids of the European 
Food Safety Authority was requested to consider evaluations of flavouring substances assessed since 
2000 by the Joint FAO/WHO Expert Committee on Food Additives (the JECFA), and to decide 
whether further evaluation is necessary, as laid down in Commission Regulation (EC) No 1565/2000. 
The present consideration concerns a group of three unsaturated delta-lactones [FL-no: 10.031, 10.037 
and 10.044] previously evaluated by the JECFA at their 49th meeting in 1997. The JECFA considered 
that further information on the metabolism of these three substances was required and that they should 
be evaluated together with other substances containing alpha,beta-unsaturation and that, therefore, 
their evaluation should be deferred. However, the EFSA Panel has considered that these three JECFA 
evaluated aliphatic lactones can be hydrolysed and metabolised to innocuous products in line with the 
aliphatic lactones evaluated by EFSA in FGE.10Rev2. The substances were evaluated through a 
stepwise approach that integrates information on structure-activity relationships, intake from current 
uses, toxicological threshold of concern, and available data on metabolism and toxicity. The Panel 
concluded that all three substances do not give rise to safety concern at their levels of dietary intake, 
estimated on the basis of the MSDI approach. 
 
© European Food Safety Authority, 2011 
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SUMMARY 
The European Food Safety Authority (EFSA) asked the Scientific Panel on Food Contact Materials, 
Enzymes, Flavourings and Processing Aids (the Panel) to provide scientific advice to the Commission 
on the implications for human health of chemically defined flavouring substances used in or on 
foodstuffs in the Member States. In particular, the Panel was requested to consider the Joint 
FAO/WHO Expert Committee on Food Additives (the JECFA) evaluations of flavouring substances 
assessed since 2000, and to decide whether no further evaluation is necessary, as laid down in 
Commission Regulation (EC) No 1565/2000. These flavouring substances are listed in the Register, 
which was adopted by Commission Decision 1999/217/EC and its consecutive amendments. 
The present flavouring group evaluation concerns the EFSA consideration of three of four unsaturated 
delta-lactones previously evaluated by JECFA at its 49th meeting in 1997. At this meeting the 
Committee considered that “For the four lactones in class III that contain alpha,beta-unsaturation 
metabolism may occur either via hydrolysis followed by beta-oxidation or via conjugation with 
glutathione. There was insufficient information from consideration of these four substances alone to 
predict the route of metabolism with confidence. The Committee considered that further information 
on the metabolism of these four substances was required and that they should be evaluated together 
with other substances containing alpha,beta-unsaturation and that, therefore, their evaluation should be 
deferred.” 
Three of the four JECFA evaluated substances are Register substances ([FL-no: 10.031], JECFA-no: 
245; [FL-no: 10.037], JECFA-no: 246 and [FL-no: 10.044], JECFA-no: 438) The mixture is not a 
Register substance and will not be considered in this Flavouring Group Evaluation 10, Revision 2 
(FGE.10Rev2). 
The Panel has considered that these three JECFA evaluated aliphatic lactones can be hydrolysed and 
metabolised to innocuous products in line with the aliphatic lactones evaluated by EFSA in 
FGE.10Rev2. The Panel concluded that these three lactones are structurally related to the group of 14 
aliphatic lactones evaluated by EFSA in FGE.10Rev2. 
The genotoxicity data available for the candidate and supporting lactones do not preclude their 
evaluation using the Procedure. 
European production volumes are available for all three substances from which a MSDI can be 
derived.  
No use levels are available for the three lactones evaluated through the Procedure. Use levels are 
needed to calculate the mTAMDIs in order to identify those flavouring substances that need more 
refined exposure assessment and to finalise the evaluation. 
In order to determine whether the conclusion for the three JECFA evaluated substances can be applied 
to the materials of commerce, it is necessary to consider the available specifications. Specifications 
including purity criteria and identity are available for all three JECFA evaluated substances. However, 
data on solubility in ethanol are lacking for [FL-no: 10.031 and 10.037] and data on solubility in water 
is lacking for [FL-no: 10.044]. 
For all three substances [FL-no: 10.031, 10.037 and 10.044] the Panel concluded that their is “no 
safety concern at estimated levels of intake as flavouring substances” based on the MSDI approach. 
KEY WORDS 
Flavourings, food safety, alpha,beta-unsaturated lactone, JECFA, FGE.10Rev2  
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BACKGROUND 
Regulation (EC) No 2232/96 of the European Parliament and the Council (EC, 1996a) lays down a 
Procedure for the establishment of a list of flavouring substances, the use of which will be authorised 
to the exclusion of all other substances in the EU. In application of that Regulation, a Register of 
flavouring substances used in or on foodstuffs in the Member States was adopted by Commission 
Decision 1999/217/EC (EC, 1999a), as last amended by Commission Decision 2009/163/EC (EC, 
2009a). Each flavouring substance is attributed a FLAVIS-number (FL-number) and all substances are 
divided into 34 chemical groups. Substances within a group should have some metabolic and 
biological behaviour in common. 
Substances which are listed in the Register are to be evaluated according to the evaluation programme 
laid down in Commission Regulation (EC) No 1565/2000 (EC, 2000a), which is broadly based on the 
Opinion of the Scientific Committee on Food (SCF, 1999a).  
Commission Regulation (EC) No 1565/2000 lays down that substances that are contained in the 
Register and will be classified in the future by the Joint FAO/WHO Expert Committee on Food 
Additives (the JECFA) so as to present no safety concern at current levels of intake will be considered 
by the European Food Safety Authority (EFSA), who may then decide that no further evaluation is 
necessary. 
In the period 2000 – 2008, during its 55th, 57th, 59th, 61st, 63rd, 65th, 68th and 69th meetings, the JECFA 
evaluated about 1000 substances, which are in the EU Register. 
TERMS OF REFERENCE 
EFSA is requested to consider the JECFA evaluations of flavouring substances assessed since 2000, 
and to decide whether no further evaluation is necessary, as laid down in Commission Regulation (EC) 
No 1565/2000 (EC, 2000a). These flavouring substances are listed in the Register which was adopted 
by Commission Decision 1999/217 EC (EC, 1999a) and its consecutive amendments. 
ASSESSMENT 
The approach used by EFSA for safety evaluation of flavouring substances is referred to in 
Commission Regulation (EC) No 1565/2000 (EC, 2000a), hereafter named the “EFSA Procedure”. 
This Procedure is based on the Opinion of the Scientific Committee on Food (SCF, 1999a), which has 
been derived from the evaluation procedure developed by the Joint FAO/WHO Expert Committee on 
Food Additives (JECFA, 1995; JECFA, 1996a; JECFA, 1997a; JECFA, 1999b), hereafter named the 
“JECFA Procedure”. The Panel on Food Contact Materials, Enzymes, Flavourings and Processing 
Aids (the Panel) compares the JECFA evaluation of structurally related substances with the result of a 
corresponding EFSA evaluation, focussing on specifications, intake estimations and toxicity data, 
especially genotoxicity data. The evaluations by EFSA will conclude whether the flavouring 
substances are of no safety concern at their estimated levels of intake, whether additional data are 
required or whether certain substances should not be put through the EFSA Procedure. 
The following issues are of special importance. 
Intake 
In its evaluation, the Panel as a default uses the Maximised Survey-derived Daily Intake (MSDI) 
approach to estimate the per capita intakes of the flavouring substances in Europe.  
In its evaluation, the JECFA includes intake estimates based on the MSDI approach derived from both 
European and USA production figures. The highest of the two MSDI figures is used in the evaluation 
by the JECFA. It is noted that in several cases, only the MSDI figures from the USA were available, 
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meaning that certain flavouring substances have been evaluated by the JECFA only on the basis of 
these figures. For Register substances for which this is the case the Panel will need EU production 
figures in order to finalise the evaluation. 
When the Panel examined the information provided by the European Flavour Industry on the use 
levels in various foods, it appeared obvious that the MSDI approach in a number of cases would 
grossly underestimate the intake by regular consumers of products flavoured at the use level reported 
by the Industry, especially in those cases where the annual production values were reported to be 
small. In consequence, the Panel had reservations about the data on use and use levels provided and 
the intake estimates obtained by the MSDI approach. It is noted that the JECFA, at its 65th meeting 
considered ”how to improve the identification and assessment of flavouring agents, for which the 
MSDI estimates may be substantially lower than the dietary exposures that would be estimated from 
the anticipated average use levels in foods” (JECFA, 2006c). 
In the absence of more accurate information that would enable the Panel to make a more realistic 
estimate of the intakes of the flavouring substances, the Panel has decided also to perform an estimate 
of the daily intakes per person using a modified Theoretical Added Maximum Daily Intake 
(mTAMDI) approach based on the normal use levels reported by Industry. 
As information on use levels for the flavouring substances has not been requested by the JECFA or 
has not otherwise been provided to the Panel, it is not possible to estimate the daily intakes using the 
mTAMDI approach for the substances evaluated by the JECFA. The Panel will need information on 
use levels in order to finalise the evaluation. 
Threshold of 1.5 Microgram/Person/Day (Step B5) Used by the JECFA 
The JECFA uses the threshold of concern of 1.5 microgram/person/day as part of the evaluation 
procedure: 
“The Committee noted that this value was based on a risk analysis of known carcinogens which 
involved several conservative assumptions. The use of this value was supported by additional 
information on developmental toxicity, neurotoxicity and immunotoxicity. In the judgement of the 
Committee, flavouring substances for which insufficient data are available for them to be evaluated 
using earlier steps in the Procedure, but for which the intake would not exceed 1.5 microgram per 
person per day would not be expected to present a safety concern. The Committee recommended that 
the Procedure for the Safety Evaluation of Flavouring Agents used at the forty-sixth meeting be 
amended to include the last step on the right-hand side of the original procedure (“Do the condition of 
use result in an intake greater than 1.5 microgram per day?”)” (JECFA, 1999b).  
In line with the Opinion expressed by the Scientific Committee on Food (SCF, 1999), the Panel does 
not make use of this threshold of 1.5 microgram per person per day. 
Genotoxicity 
As reflected in the Opinion of SCF (SCF, 1999a), the Panel has in its evaluation focussed on a 
possible genotoxic potential of the flavouring substances or of structurally related substances. 
Generally, substances for which the Panel has concluded that there is an indication of genotoxic 
potential in vitro, will not be evaluated using the EFSA Procedure until further genotoxicity data are 
provided. Substances for which a genotoxic potential in vivo has been concluded, will not be evaluated 
through the Procedure. 
Specifications 
Regarding specifications, the evaluation by the Panel could lead to a different opinion than that of 
JECFA, since the Panel requests information on e.g. isomerism. 
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Structural Relationship  
In the consideration of the JECFA evaluated substances, the Panel will examine the structural 
relationship and metabolism features of the substances within the flavouring group and compare this 
with the corresponding FGE. 
HISTORY OF THE EVALUATION OF THE SUBSTANCES IN THE PRESENT FGE 
The present flavouring group evaluation concerns the EFSA consideration of three of four unsaturated 
delta-lactones previously evaluated by the JECFA at their 49th meeting in 1997. At this meeting the 
Committee considered that “For the four lactones in class III that contain alpha,beta-unsaturation, 
metabolism may occur either via hydrolysis followed by beta-oxidation or via conjugation with 
glutathione. There was insufficient information from consideration of these four substances alone to 
predict the route of metabolism with confidence. The JECFA Committee considered that further 
information on the metabolism of these four substances was required and that they should be evaluated 
together with other substances containing alpha,beta-unsaturation and that, therefore, their evaluation 
should be deferred.” 
The alpha,beta-unsaturated aldehyde and ketone structures are structural alert for genotoxicity (EFSA, 
2008b). Accordingly the three JECFA evaluated alpha,beta-unsaturated Register substances, which are 
alpha,beta-unsaturated ketones and lactones, were allocated to FGE.19 (EFSA, 2008b). On the other 
hand, it is a common anticipation that esters of carboxylic acids and alcohols are readily hydrolysed to 
the corresponding acids and alcohols. This also accounts for aliphatic lactones (EFSA, 2011p). In this 
case the structural alert for genotoxicity is lifted and the three substances can be evaluated using the 
Procedure.  
1. Presentation of the Substances in the JECFA Flavouring Group 
1.1. Description 
1.1.1. JECFA Status 
At its 49th meeting the JECFA evaluated a group of thirty five aliphatic lactones. Four of these 
lactones contain alpha,beta-unsaturation (JECFA-no: 245, 246, 438 and a mixture of three alpha,beta-
unsaturated lactones). For the four alpha,beta-unsaturated substances the JECFA concluded that the 
evaluation should be “deferred pending the general consideration of substances containing alpha,beta-
unsaturation” (JECFA, 1998a). 
1.1.2. EFSA Considerations 
Three of the four JECFA-evaluated substances are Register substances ([FL-no: 10.031], JECFA-no: 
245; [FL-no: 10.037], JECFA-no: 246 and [FL-no: 10.044], JECFA-no: 438), the mixture is not a 
Register substance and will not be considered in this FGE. 
1.2. Isomers 
1.2.1. JECFA Status 
Two of the three JECFA evaluated substances possess a chiral centre [FL-no: 10.037 and 10.044]. 
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1.2.2. EFSA Considerations 
The Flavouring Industry has provided information about the configuration of the chiral centre for [FL-
no: 10.037 and 10.044] (EFFA, 2011a), as each exist as racemate.  
1.3. Specifications 
1.3.1. JECFA Status 
The JECFA specifications are available for all three substances. 
1.3.2. EFSA Considerations 
The specifications are not considered adequate for the three substances. Data on solubility in ethanol 
are lacking for [FL-no: 10.031 and 10.037] and data on solubility in water is lacking for [FL-no: 
10.044] (See Section 1.2). 
2. Intake Estimations 
2.1. JECFA Status 
European production volumes are available for all three JECFA evaluated substances. 
2.2. EFSA Considerations 
No comments.  
3. Genotoxicity Data 
3.1. Genotoxicity Studies – Text taken4 from the JECFA (JECFA, 1998a) 
In vitro / in vivo 
There are in vitro / in vivo genotoxicity studies available for seven of the 35 JECFA evaluated 
lactones. No description or conclusion has been given by JECFA on these genotoxicity studies. 
A summary of the studies are given in Table 2.1. 
3.2. Genotoxicity Studies - Text taken5 from EFSA FGE.10Rev2 (EFSA, 2011p) 
Only text relevant for the evaluation of the three alpha,beta-unsaturated lactones is included: 
Genotoxicity data were provided for two candidate substances, pentano-1,5-lactone [FL-no: 10.055] 
and 5,6-dimethyl-tetrahydro-pyran-2-one [FL-no: 10.168], which both were reported to be negative in 
microbial mutagenicity assays (Kuroda et al., 1986; Uhde, 2004a). 
Genotoxicity tests are available for ten supporting substances. Some positive results from in vitro 
studies are reported for 4-hydroxybutyric acid lactone [FL-no: 10.006], which, however, was found 
                                                     
 
4 The text is taken verbatim from the indicated reference source, but text related to substances not included in the present FGE has been removed. 
5 The text is taken verbatim from the indicated reference source, but text related to substances not included in the present FGE has been removed. 
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negative in a Drosophila sex-linked recessive lethal mutation assay (Table 2.3). Results of in vivo 
bone marrow micronucleus assays in mice available for 4-hydroxybutyric acid lactone were also 
negative, however, since the PCE/NCE ratio was not reported it is not clear if the test substance 
reached the bone marrow (Table 2.3). Positive in vitro data that cannot be evaluated are reported for 
hexano-1,5-lactone [FL-no: 10.010], nonano-1,4-lactone [FL-no: 10.001], undecano-1,4-lactone [FL-
no: 10.002] and undecano-1,5-lactone [FL-no: 10.011] (Table 2.2). 
Conclusions on genotoxicity 
For the candidate lactones, the genotoxic potential cannot be assessed adequately, however, from the 
limited data available there were no indications that genotoxicity for these substances should give rise 
to safety concern. 
For a summary of in vitro / in vivo genotoxicity data considered by EFSA see Tables 2.2 and 2.3.  
3.3. EFSA Considerations 
The genotoxicity data available do not preclude the evaluation of the candidate substances through the 
Procedure. 
4. Application of the Procedure 
4.1. Application of the Procedure to three aliphatic lactones considered by JECFA (JECFA, 
1998a) 
The JECFA did not evaluate the three aliphatic lactones through the Procedure as the evaluation were 
deferred pending evaluation of other alpha,beta-unsaturated substances. 
4.2. Application of the Procedure by EFSA in FGE.10Rev2 (EFSA, 2011p) 
Only text relevant for the evaluation of the three candidate aliphatic alpha,beta-unsaturated lactones 
in the present FGE has been included. 
For the safety evaluation of the 14 candidate lactones from chemical groups 9 the Procedure as 
outlined in Annex I (of FGE.10Rev2) was applied, based on the MSDI approach. The stepwise 
evaluations of the 14 substances are summarised in Table 3.2. 
Step 1 
The 14 candidate lactones are classified according to the decision tree approach by Cramer et al. 
(1978) into structural class I. 
Step 2 
The 14 candidate lactones are considered to be metabolised to innocuous products, accordingly the 
evaluation of these 14 substances proceeds via the A-side of the Procedure. 
Step A3 
Step A3 applies to 14 candidate lactones from structural class I [FL-no: 10.038, 10.039, 10.040, 
10.045, 10.047, 10.048, 10.049, 10.052, 10.055, 10.058, 10.059, 10.063, 10.068 and 10.168]. 
The 14 candidate substances which have been assigned to structural class I have estimated European 
daily per capita intakes (MSDI) ranging from 0.0061 to 48 microgram. These intakes are below the 
thresholds of concern of 1800 microgram/person/day for structural class I. 
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Accordingly, these 14 candidate lactones do not pose a safety concern when used at estimated levels 
of intake as flavouring substances, based on the MSDI approach. 
4.3. EFSA Considerations 
The metabolism of alpha,beta-unsaturated delta-lactones has been previously discussed by the JECFA 
at the 49th meeting in 1997. Based upon a study by Köppel and Tenczer (1991), the JECFA concluded 
that hydrolysis of the alpha,beta-unsaturated delta-lactones to the corresponding ring-opened 
hydroxycarboxylic acids may occur, but that there is no information available to predict that this is the 
major route of metabolism. However, Köppel and Tenczer (1991) analysed the metabolism of D,L-
kawain ((2R)-4-methoxy-2-[(E)-2-phenylethenyl]-2,3-dihydropyran-6-one). Due to the aromatic ring 
and the hydroxyl-group the Panel considered that this substance is not sufficiently structurally related 
to the candidate substances [FL-no: 10.031, 10.037 and 10.044]. Therefore, no conclusion on the 
hydrolysis of the candidate substances can be drawn from the study by Köppel and Tenczer (Köppel & 
Tenczer, 1991).  
 
Alternatively, the JECFA considered that alpha,beta-unsaturated delta-lactones may be conjugated 
with glutathione and be excreted as the cysteine or mercapturic acid adducts. The study by Boyland 
and Chassaud (1970) revealed that a high dose of 5-hydroxyhexenoic acid lactone (0.134 mg/kg) 
significantly reduced rat liver glutathione levels upon intraperitoneal injection. However, the use of 
the intraperitoneal route of administration circumvents the gastroinstestinal tract where environmental 
conditions favour hydrolysis of lactones. In FGE.05 data have described that esters of alpha,beta-
unsaturated carboxylic acids will deplete liver GSH levels after intraperitoneal administration. 
Pretreatment with an inhibitor of esterase activity resulted in a much larger GSH depletion which 
indicates that ester hydrolysis e.g. by favourable conditions in the G.I.-tract, will reduce the toxicity of 
these lactones. Therefore, the Panel considered the study by Boyland and Chassaud (Boyland & 
Chasseaud, 1970) of little relevance for the evaluation of the candidate substances [FL-no: 10.031, 
10.037 and 10.044] when used as flavouring substances in food. 
 
Overall, the Panel concluded that in line with the candidate lactones in FGE.10Rev2, the three JECFA 
evaluated lactones [FL-no: 10.031, 10.037 and 10.044] are anticipated to be metabolised to innocuous 
products and can accordingly be evaluated via the A-side of the Procedure. The three lactones were 
allocated to structural class III to which a threshold of concern of 90 microgram per person per day has 
been assigned. The estimated European daily per capita intakes for these three substances [FL-no: 
10.031, 10.037 and 10.044] are 84, 830 and 0.12 microgram, respectively. The intakes are below the 
class threshold of 90 microgram per person per day for the two substances [FL-no: 10.031 and 10.044] 
but above for [FL-no: 10.037]. 
 
Accordingly, two of the three lactones do not pose a safety concern when used at estimated levels of 
intake as flavouring substances, based on the MSDI approach. As the substance [FL-no: 10.037] is not 
endogenous a NOAEL for the substance or a structural related substance has to be provided. In a 90 
day study in rats by Cox et al. (Cox et al., 1974h) a NOAEL of 12.1 mg/kg bw/day could be 
established for the structural related substance [FL-no: 10.031]. This carefully performed one dose 
study is not in compliance with a specific testing guideline but is of sufficient quality to accept the 
data. Compared to the MSDI of 830 microgram/capita/day (equal to 13.8 microgram/kg bw/day), this 
NOAEL provides a margin of safety of ca. 900. 
5. Conclusion 
The present flavouring group evaluation concerns the EFSA consideration of three of four alpha,beta-
unsaturated delta-lactones previously evaluated by the JECFA at its 49th meeting in 1997. At this 
meeting the Committee considered that “For the four lactones in class III that contain alpha,beta-
unsaturation metabolism may occur either via hydrolysis followed by beta-oxidation or via 
conjugation with glutathione. There was insufficient information from consideration of these four 
Flavouring Group Evaluation 98
 
 
10 EFSA Journal 2011; 9(7):2179 
substances alone to predict the route of metabolism with confidence. The Committee considered that 
further information on the metabolism of these four substances was required and that they should be 
evaluated together with other substances containing alpha,beta-unsaturation and that, therefore, their 
evaluation should be deferred.” 
Three of the four JECFA evaluated substances are Register substances ([FL-no: 10.031], JECFA-no: 
245; [FL-no: 10.037], JECFA-no: 246 and [FL-no: 10.044], JECFA-no: 438). The mixture is not a 
Register substance and will not be considered in this FGE. 
The Panel has considered that these three JECFA evaluated aliphatic lactones can be hydrolysed and 
metabolised to innocuous products in line with the aliphatic lactones evaluated by EFSA in 
FGE.10Rev2. The Panel concluded that the three lactones are structurally related to the group of 14 
aliphatic lactones evaluated by EFSA in FGE.10Rev2. 
The genotoxicity data available for the candidate and supporting lactones do not preclude their 
evaluation using the Procedure. 
European production volumes are available for all three substances from which a MSDI can be 
derived.  
No use levels are available for the three lactones evaluated through the Procedure. Use levels are 
needed to calculate the mTAMDIs in order to identify those flavouring substances that need more 
refined exposure assessment and to finalise the evaluation. 
In order to determine whether the conclusion for the three JECFA evaluated substances can be applied 
to the materials of commerce, it is necessary to consider the available specifications. Specifications 
including purity criteria and identity are available for all three JECFA evaluated substances. However, 
data on solubility in ethanol are lacking for [FL-no: 10.031 and 10.037] and data on solubility in water 
is lacking for [FL-no: 10.044].  
For all three substances [FL-no: 10.031, 10.037 and 10.044] the Panel concluded that their is “no 
safety concern at estimated levels of intake as flavouring substances” based on the MSDI approach. 
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TABLE 1: SPECIFICATION SUMMARY  
Table 1: Specifications Summary for the JECFA Evaluated Substances in the Present Group (JECFA, 1998b; JECFA, 2000d) 
Table 1: Specification Summary of the Substances in the JECFA Flavouring Group of three aliphatic lactones (JECFA, 1998b; JECFA, 2000d) 
FL-no 
JECFA-
no 
EU Register name Structural formula FEMA no 
CoE no 
CAS no 
Phys.form 
Mol.formula 
Mol.weight 
Solubility 1) 
Solubility in ethanol 
2) 
Boiling point, °C 
3) 
Melting point, °C 
ID test 
Assay minimum 
Refrac. 
Index 4) 
Spec.gravity 
5) 
EFSA comments 
10.031 
245 
6-Pentyl-2H-pyran-2-one O O
 
3696 
10967 
27593-23-3 
Liquid 
C10H14O2  
166.22 
Insoluble 
 
85 (3 hPa) 
 
IR 
98.7 % 
1.501-1.509 
1.000-1.009 
 
 
10.037 
246 
Dec-2-eno-1,5-lactone   6) O O
 
3744 
 
54814-64-1 
Liquid 
C10H16O2   
168.24  
Insoluble 
 
112 (2 hPa) 
 
IR 
95 % 
1.462-1.482 
0.947-0.987 
(20°/20° 
 
JECFA evaluated 5-
hydroxy-2-decenoic acid 
delta-lactone (CASrn no. 
51154-96-2, corresponding 
to R-enantiomer). Register 
CASrn no refers to the 
racemate. 
Racemate (EFFA, 2011a). 
10.044 
438 
Dodec-2-eno-1,5-lactone   6) OO
 
3802 
 
16400-72-9 
Liquid 
C12H20O2    
196.3  
 
Soluble 
115 (3 hPa) 
 
IR 
95 % 
1.467-1.473 
1.470-1.480 
Racemate (EFFA, 2011a). 
 
1) Solubility in water, if not otherwise stated. 
2) Solubility in 95 %  ethanol, if not otherwise stated. 
3) At 1013.25 hPa, if not otherwise stated. 
4) At 20°C, if not otherwise stated. 
5) At 25°C, if not otherwise stated. 
6) Stereoisomeric composition not specified. 
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TABLE 2: GENOTOXICITY DATA  
Table 2.1: Genotoxicity Data (in vitro / in vivo) for Aliphatic Lactones (JECFA, 1998a)  
Table 2.1: Summary of Genotoxicity Data of Aliphatic Lactones Evaluated by the JECFA (JECFA, 1998a) 
Chemical Name [FL-no:] Endpoint Test Object  Concentration / Dose Result  Reference  
4-Hydroxybutyric acid lactone (gamma-
Butyrolactone) 
Gene mutation S. typhimurium TA1535, TA98, TA100 0.1-50 µmoles/plate1 negative (Loquet et al., 1981) 
Gene mutation S. typhimurium TA98, TA100, TA102 0.013-1.3 mmol1 negative (Aeschbacher et al., 1989) 
Gene mutation S. typhimurium TA98, TA100, TA1535, TA1537 100-10 000 µg/plate
1 negative (NTP, 1992e) 
Gene mutation S. typhimurium TA98, TA100, TA1535, TA1537 0-10 000 µg/plate
1 negative (Haworth et al., 1983) 
Gene mutation S. typhimurium TA98, TA100, TA1537 5000 µg/plate1 negative (MacDonald, 1981) 
Gene mutation S. typhimurium TA98, TA100, TA1535, TA1537 500 µg/plate
1 negative (Garner et al., 1981) 
Gene mutation S. typhimurium TA100, TA1535, TA1537, TA1538 4-2500 µg/plate
1 negative (Trueman, 1981) 
Gene mutation S. typhimurium TA92, TA98, TA100, TA1537, TA1538, TA1535 0.2-2000 µg/plate
1 negative (Brooks and Dean, 1981) 
Gene mutation S. typhimurium TA98, TA100, TA1535, TA1537, TA1538 1000 µg/plate negative (Baker and Bonin, 1981) 
Gene mutation S. typhimurium TA98, TA100, TA1535, TA1537, TA1538 500 µg/plate negative (Rowland and Severn, 1981) 
Gene mutation S. typhimurium TA98, TA100, TA1535, TA1537, TA1538 500 µg/plate
1 negative (Simmon and Shephard, 1981) 
Gene mutation S. typhimurium TA98, TA100, TA1537 not reported1 negative (Nagao and Takahashi, 1981) 
Gene mutation S. typhimurium TA98, TA100, TA1535, TA1537, TA1538 10-10 000 µg/plate
1 negative (Richold and Jones, 1981) 
Gene mutation S. typhimurium TA98, TA100 500 - 1000 µg/ml negative (Ichinotsubo et al., 1981a) 
Fluctuation Test S. typhimurium TA98, TA100 500 µg/ml1 negative (Hubbard et al., 1981) 
Forward mutation S. typhimurium TM677 1000 µg/ml2 negative (Skopeck et al., 1981) 
Microtiter fluctuation S. typhimurium TA98, TA1535, TA1537 10-1000 µg/ml1 negative (Gatehouse, 1981) 
Gene mutation E. coli 500 µg/plate1 negative (Venitt and Crofton-Sleigh, 1981) 
Gene mutation E. coli SA500 250 µg/plate lethal (Dambly et al., 1981) 
Differential killing test E. coli WP2, WP67 & M871 2500 µg/plate1 negative (Green, 1981) 
Differential killing assay E. coli P2,WP67 & CM871 1000 µg/ml1 negative (Tweats, 1981) 
Microtiter fluctuation E. coli WP2 uvrA 10-1000 µg/ml1 negative (Gatehouse, 1981) 
 Gene mutation E. coli WP2 uvrA pKM102 not reported1 negative (Matsushima et al., 1981) 
Sister chromatid exchange Chinese hamster ovary cells 
148-1480 µg/ml3 
494-4940 µg/ml2  
3010-5010 µg/ml2 
negative  
positive (weak)6  
positive6 
(NTP, 1992e) 
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Table 2.1: Summary of Genotoxicity Data of Aliphatic Lactones Evaluated by the JECFA (JECFA, 1998a) 
Chemical Name [FL-no:] Endpoint Test Object  Concentration / Dose Result  Reference  
Chromosome aberration Chinese hamster ovary cells 
500-4990 µg/ml3  
400-3990 µg/ml2  
2210-2950 µg/ml2 
negative  
positive6  
positive6 
(NTP, 1992e) 
ADP-ribosyl transf. act. Human FL cells 10-3 to 10-7 mol/l negative (Yingnian et al., 1990) 
Polyploidy Human leucocyte 0.7 mmol/litre negative (Withers, 1966) 
Gene Mutation Schizosaccha romyces pombe  20 µg/ml1 negative (Loprieno, 1981) 
Mitotic crossing- over S. cervevisiae 1000 µg/ml negative (Kassinova et al., 1981) 
Rec assay B. subtilis H17, M45 20 µl/disc4 positive6 (Kada, 1981) 
Unscheduled DNA synthesis Human HeLa S3 cells 0.1-100 µg/ml1 negative (Martin and McDermid, 1981) 
Mitotic gene conversion S. cerevisiae 750 µg/ml1 negative (Sharp and Parry, 1981) 
Clastogenic activity Rat liver cell line RL1 250 µg/ml negative (Dean, 1981) 
Mammalian cell transformation BHK21C1B/HRC1 cells 2500 µg/ml1 ?5 (Daniel and Dehnel, 1981) 
Mammalian cell transformation BHK-21 hamster kidney cells 250 µg/ml2 positive (Styles, 1981) 
Degranulation assay Rat 25 mg/ml positive (Fey et al., 1981) 
Cell growth inhibition S. cerevisiae 750 µg/ml1 negative (Sharp and Parry, 1981) 
Haploid yeast reversion S. cerevisiae 222 µg/ml1 ?5 (Mehta and von Borstel, 1981) 
DNA pol I inhibition E. coli W3110 & P3478 330 µg/plate positive
3 
negative2 (Rosenkranz et al., 1981) 
Sperm head abnormality (CBA x Balb/c)F1 mice 0.1-1.0 mg/kg/ day ip (5 days) negative (Topham, 1981) 
Sex-linked recessive test Drosophila melanogaster 20 000 or 28 000 mg/ kg (diet) or 15 000 mg/kg (injection) negative (Foureman et al., 1994) 
Micronucleus test B6C3F1 mice 0.7 mg/kg/day ip (2 days) negative (Katz et al., 1981) 
Micronucleus test B6C3F1 mice 80 % LD50 ip (2 days) negative (Salamone et al., 1981) 
Micronucleus test CD-1 mice 0.11-0.44 mg/kg/day ip (2 days) negative (Tsuchimoto and Matter, 1981) 
gamma-Heptalactone Gene mutation S. typhimurium TA98, TA100, TA1535, TA1537, TA1538 100 000 µg/plate
1 negative (Heck et al., 1989) 
UDS Rat hepatocytes 3000 µg/ml negative (Heck et al., 1989) 
gamma-Nonalactone Gene mutation S. typhimurium TA98, TA100, TA1535, TA1537, TA1538 37 500 µg/plate
1 negative (Heck et al., 1989) 
Gene mutation Human leucocytes 0.7 mM positive (Withers, 1966) 
Gene mutation Mouse lymphoma L5178y TK+/- 1000 µg/ml 400 µg/ml negative
3  
positive2 (Heck et al., 1989) 
UDS Rat hepatocytes 500 µg/ml negative (Heck et al., 1989) 
Gene mutation E. coli WP2 uvrA 0.2-1.6 mg/plate negative (Yoo, 1986) 
Rec-assay B. subtilis 20 µl/disk positive (Yoo, 1986) 
gamma-Undecalactone Gene mutation S. typhimurium TA92, TA94, TA98, TA100, TA1535, TA1537 5000 µg/plate
1 negative (Ishidate et al., 1984) 
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Table 2.1: Summary of Genotoxicity Data of Aliphatic Lactones Evaluated by the JECFA (JECFA, 1998a) 
Chemical Name [FL-no:] Endpoint Test Object  Concentration / Dose Result  Reference  
Gene mutation S. typhimurium TA97, TA102 100 µg/plate negative (Fujita and Sasaki, 1987) 
Chromosome aberration Chinese hamster fibroblast 500 µg/ml negative (Ishidate et al., 1984) 
Rec-assay B. subtilis H17 & M45 19 µg/disc negative (Oda et al., 1978) 
Rec-assay B. subtilis H17 & M45 10 µl/disc positive (Yoo, 1986) 
Rec-assay B. subtilis H17 & M45 10 µl/disc positive
2 
negative1 (Kuroda et al., 1984a) 
Mouse micronucleus 2-6 ddY male mice 250-2000 mg/kg/day ip (2 days) negative (Hayashi et al., 1988) 
5-Hydroxyundecanoic acid delta-lactone Rec-assay B. subtilis H17 & M45 19 µg/disc negative (Oda et al., 1978) 
omega-Pentadecalactone Gene mutation S. typhimurium TA98, TA100, TA102 50 µmol/plate1 negative (Aeschbacher et al., 1989) 
Chromosome aberration Human leukocytes 70 µmole/ml negative (Withers, 1966) 
1,4-Dodec-6-enolactone Gene mutation S. typhimurium TA98, TA100, TA1535, TA1537 500 µg/plate
1 negative (Watanabe and Kinosaki, 1990) 
Rec-assay E. coli WP2 uvrA 500 µg/plate1 negative (Watanabe and Kinosaki, 1990) 
1 With and without rat liver S-9 metablic activation. 
2 With rat liver S-9 metabolic activation. 
3 Without rat liver S-9 metabolic activation. 
4 With yellowtail S-9 metabolic activation. 
5 Ambiguous result. 
6 These positive results with gamma-butyrolacone were only seen at relatively high dose levels and may be artifactual. There was no evidence of positive genotoxicity in in vivo studies. Overall, the genotoxicity of gamma-butyrolactone was 
considered to be negative. 
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Table 2.2: Genotoxicity Data (in vitro) EFSA / FGE.10Rev2 (EFSA, 2011p) 
Only studies relevant for the evaluation of the three candidate aliphatic alpha,beta-unsaturated lactones in the present FGE has been included 
Table 2.2: GENOTOXICITY (in vitro) 
Chemical Name [FL-no:] Endpoint Test Object  Concentration / Dose Result  Reference  Comments 
(Butyro-1,4-lactone [10.006]) Ames test  S. typhimurium TA98, TA100, TA1535 0.1-50 µmoles/plate (8.6 - 4305 
µg/plate) 
Negative1 
 
(Loquet et al., 1981) No control values are given for 
inactive compounds. Conclusion 
not comprehensible.  
Ames test  S. typhimurium TA98, TA100, TA102 0.013 -1.3 mmol (11.2 - 1120 
µg/ml) 
Negative1  (Aeschbacher et al., 1989)  
Ames test  S. typhimurium TA98, TA100, TA1535, 
TA1537 
100-10000 µg/plate Negative1  (NTP, 1992e)  
Ames test  S. typhimurium TA98, TA100, TA1537, 5,000 or 2000 µg/plate  Negative1  (MacDonald, 1981)  
Ames test  S. typhimurium TA98, TA100, TA1535, 
TA1537 
0-10000 µg/plate Negative1  (Haworth et al., 1983)  
Ames test  S. typhimurium TA98, TA100, TA1535, 
TA1537 
NR  Negative1  (Garner et al., 1981)  
Ames test  S. typhimurium TA98,TA100, TA1535, 
TA1537, TA1538 
4-2500 µg/plate Negative1  (Trueman, 1981)  
Ames test  S. typhimurium TA92, TA98, TA100, 
TA1535, TA1537, TA1538 
0.2-2000 µg/plate Negative1  (Brooks and Dean, 1981)  
Ames test  S. typhimurium TA98, TA100, TA1535, 
TA1537, TA1538 
10000 µg/ml  Negative1  (Baker and Bonin, 1981)  
Ames test  S. typhimurium TA98, TA100, TA1535, 
TA1537, TA1538 
500 µg/plate  Negative1  (Rowland and Severn, 
1981) 
 
Ames test  S. typhimurium TA98, TA100, TA1535, 
TA1537, TA1538 
500 µg/plate  Negative1  (Simmon and Shephard, 
1981) 
 
Ames test  S. typhimurium TA98, TA100,  TA1537 NR  Negative1  (Nagao and Takahashi, 
1981) 
 
Ames test  S. typhimurium TA98, TA100,  1000 mg  Negative1  (Ichinotsubo et al., 1981a)  
Ames test  S. typhimurium TA98, TA100, TA1535, 
TA1537, TA1538 
10 - 10000 µg/plate  Negative3  (Richold and Jones, 1981)  
Reverse bacterial mutation 
assay 
E. coli WP2 (p) up to 500 µg/plate (high dose 
studies) 
up to 100 µg/plate (low dose 
studies) 
Negative3  (Venitt and Crofton-
Sleigh, 1981) 
 
Reverse bacterial mutation 
assay 
E. coli  SA500  NR  Lethal4  (Dambly et al., 1981) Authors state “toxic, preventing 
adequate testing“. 
Reverse mutation assay E. coli WP2 uvrA  
pKM102 
NR  Negative1  (Matsushima et al., 1981)  
Forward mutation assay S. typhimurium TM677 1000 µg/ml  Negative3  (Skopeck et al., 1981)  
Microtiter fluctuation test S. typhimurium TA98, TA1535, TA1537 10 - 1000 µg/ml  Negative3  (Gatehouse, 1981)  
Microtiter fluctuation test S. typhimurium TA98, TA100 NR  Negative3  (Hubbard et al., 1981)  
 Microtiter fluctuation test E. coli WP2 uvrA  10 - 1000 µg/ml  Negative3  (Gatehouse, 1981)  
Rec-assay  Bacillus subtilis H17, M45 20 µl (20000 µg) Positive1 (Kada, 1981) Reliable study, conclusion 
comprehensible. 
Differential killing test E. coli WP2 pol A, WP2 uvrA, WP67 
uvrA, WP67 pol A, CM871 uvrA recA, 
NR  Negative1  (Green, 1981)  
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Table 2.2: GENOTOXICITY (in vitro) 
Chemical Name [FL-no:] Endpoint Test Object  Concentration / Dose Result  Reference  Comments 
LexA 
Differential killing test E. coli WP2 pol A, WP2 uvrA, WP67 
uvrA, WP67 pol A, CM871 uvrA recA, 
LexA 
1000 µg/ml  Negative2  (Tweats, 1981)  
Mitotic crossing-over S. cerevisiae  1000 µg/ml  Negative1  (Kassinova et al., 1981)  
Mitotic gene conversion S. cerevisiae (JDI) 750 µg/ml  Negative2  (Sharp and Parry, 1981)  
Cell growth inhibition S. cerevisiae (JDI) 750 µg/ml  Negative2  (Sharp and Parry, 1981)  
DNA polymerase I inhibition 
test 
E. coli  W3110 & P3478 10 µl (10000 µg) Positive2 
Negative3 
(Rosenkranz et al., 1981) Reliable study, conclusion 
comprehensible. 
Forward mutation assay S. Pombe  20 µg/ml1  Negative3  (Loprieno, 1981)  
Unscheduled DNA synthesis Human HeLa S3 cells 0.1-100 µg/ml  Negative1  (Martin and McDermid, 
1981) 
 
ADP-ribosyl transferase 
activity 
Human FL cells  10-3 to 10-7 mol/L 
(0.0086 – 86 µg/ml)3   
Negative  (Yingnian et al., 1990)  
Clastogenic activity Rat liver cell line RL1 250 µg/ml  Negative  (Dean, 1981)  
Mammalian cell 
transformation 
BHK-21 hamster kidney cells 250 µg/ml Positive1 (Styles, 1981) No specific genotoxicity 
endpoint. 
Degranulation assay Rat  25 mg/ml (25000 µg/ml) Positive  (Fey et al., 1981) No genetic endpoint 
(displacement of polysomes from 
ER). 
Sister chromatid exchange Chinese hamster ovary cells 494-4940 µg/ml 
494-1480 µg/ml 
3010-4940 µg/ml 
Negative2  
Negative3 
Positive3 
(NTP, 1992e) Study in complinace with NTP 
laboratory health and safety 
requirements, conclusion 
comprehensible. 
Chromosomal aberration   Chinese hamster ovary cells 400-2580 µg/ml 
400-1500 µg/ml 
>2580 µg/ml 
Negative2
Negative3 
Positive3 
(NTP, 1992e) Study in complinace with NTP 
laboratory health and safety 
requirements, conclusion 
comprehensible. Cells were 
selected for scoring on the basis 
of good morphology and 
completeness of karyotype. 
Pentano-1,5-lactone [10.055]  Microbial assay  E. coli  B/rWP2(trp-), WP2(trp-), 
WP2(uvrA-) 
1 – 3 mg/plate (1000-3000 
µg/plate) 
Negative5 (Kuroda et al., 1986) Review, data cannot be validated. 
(Hexano-1,5-lactone  [10.010])  Ames test  S. typhimurium  TA98, TA100 NR  Negative2  (Kawachi et al., 1980b) Summary of results on 186 
compounds. No details on 
methods, concentrations and data 
given, results cannot be validated. 
Rec-assay  B. subtilis  NR  Negative2  (Kawachi et al., 1980b) Summary of results on 186 
compounds. No details on 
methods, concentrations and data 
given, results cannot be validated. 
Sister chromatid exchange Hamster lung fibroblast cells NR  Negative3  (Kawachi et al., 1980b) Summary of results on 186 
compounds. No details on 
methods, concentrations and data 
given, results cannot be validated. 
Chromosomal aberration Hamster lung fibroblast cells NR  Positive2  (Kawachi et al., 1980b) Summary of results on 186 
compounds. No details on 
methods, concentrations and data 
given, results cannot be validated. 
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Table 2.2: GENOTOXICITY (in vitro) 
Chemical Name [FL-no:] Endpoint Test Object  Concentration / Dose Result  Reference  Comments 
Chromosomal aberration  Human embryo fibroblast cells NR  Negative3  (Kawachi et al., 1980b) Summary of results on 186 
compounds. No details on 
methods, concentrations and data 
given, results cannot be validated. 
(Heptano-1,4-lactone  [10.020]) Ames test  S. typhimurium TA98, TA100, TA1535, 
TA1537, TA1538 
100,000 µg/plate Negative1 (Heck et al., 1989) Abstract only, study cannot be 
validated. 
Unscheduled DNA synthesis Rat hepatocytes  3000 µg  Negative1  (Heck et al., 1989) Abstract only, study cannot be 
validated. 
(Nonano-1,4-lactone  [10.001]) Ames test  S. typhimurium TA98, TA100, TA1535, 
TA1537, TA1538 
37500 µg/plate Negative1  (Heck et al., 1989) Abstract only, study cannot be 
validated. 
Mammalian  Mouse lymphoma L5178y TK+/- 1000 µg/ml  
600 µg/ml 
Negative2 
Positive3 
(Heck et al., 1989) Abstract only, study cannot be 
validated. 
Unscheduled DNA synthesis Rat hepatocytes  500 µg  Negative1  (Heck et al., 1989) Abstract only, study cannot be 
validated. 
Mutation assay       E. coli WP2 uvrA 0.2-1.6 mg/plate (200-1600 
µg/plate) 
Negative4 (Yoo, 1986) Methods in Japanese, tables only 
in English. Study cannot be 
validated. 
Rec-assay  B. subtilis M45 & H17 20 µl/disk (20000 µg/disk) Positive4  (Yoo, 1986) Methods in Japanese, tables only 
in English. Study cannot be 
validated. 
(Undecano-1,4-lactone  [10.002]) Ames test  S. typhimurium TA92, TA94, TA98, 
TA100, TA1535, TA1537, TA2637 
5 mg/plate (5000 µg/plate) Negative1  (Ishidate et al., 1984)  
Ames test  S. typhimurium TA97, TA98, TA100, 
TA102 
0.1 mg/disk (100 µg/disk) Negative1  (Fujita and Sasaki, 1987)  
Rec-assay  B. subtilis H17 & M45 19 µg  Negative1  (Oda et al., 1979)  
Rec-assay  B. subtilis H17 & M45 10 µl/plate (10000 µg/plate) Positive6 (Yoo, 1986) Methods in Japanese, tables only 
in English. Study cannot be 
validated. 
Rec-assay  B. subtilis H17 & M45 10 µl/plate  (10000 µg/plate) Positive3 
Negative2 
(Kuroda et al., 1984a) Abstract only translated, study 
cannot be validated. 
Chromosomal aberration  Chinese hamster fibroblast 0.5 mg/ml (500 µg/ml) Negative1  (Ishidate et al., 1984)  
(Undecano-1,5-lactone   [10.011])  Rec-assay B. subtilis H17 & M45 19 µg Negative1 (Oda et al., 1979)  
Rec-assay  B. subtilis  10 µl/plate (10000 µg/plate) Positive1  (Kuroda et al., 1984a) Abstract only translated, study 
cannot be validated. 
(Pentadecano-1,15-lactone  [10.004]) Ames test  S. typhimurium TA98, TA100, TA102 50 µmol (12 µg/ml)  Negative1  (Aeschbacher et al., 1989)  
(5-Methylfuran-2(3H)-one  [10.012]) Ames test  S. typhimurium TA98, TA100 5 - 50 µg/plate  Negative1  (Turek et al., 1997)  
(Dodec-6-eno-1,4-lactone  [10.009]) 
  
Ames test  S. typhimurium TA98, TA100, TA1535, 
TA1537 
500 µg/plate  Negative1  (Watanabe and Morimoto, 
1990) 
 
Rec-assay  E. coli WP2 uvrA  500 µg/plate  Negative1  (Watanabe and Morimoto, 
1990) 
 
(3-Hydroxy-4,5-dimethylfuran-
2(5H)-one  [10.030]) 
Formation of 32P-labelled 
DNA fragment (test on 
isolated DNA). 
p53 tumour suppression gene 1mM (128 µg/ml) Negative7  (Yamashita et al., 1998)  
5,6-Dimethyl-tetrahydro-pyran-2-one 
[10.168] 
Ames test S. typhimurium TA98, TA100, TA102, 
TA1535, TA1537 
5000 microgram/plate Negative1 (Uhde, 2004a) Test performed both in the 
incorporation and preincubation 
assays. 
NR: Not reported 
1 With and without S-9 metabolic activation.  
Flavouring Group Evaluation 98
 
 
18 EFSA Journal 2011; 9(7):2179 
2 Without S-9 metabolic activation.  
3 With S-9 metabolic activation.  
4 Presence or absence of metabolic activation not specified.  
5 Anti-mutagenic effects study.  
6 Presence or absence of metabolic activation not specified.  
7 4,5-dimethyl-3-hydroxy-2,5-dihydrofuran-2-one did not form DNA adducts, but 2,5-DMHF does. Study addresses mechanism of chemical reaction of 2,5-dimethyl-4-hydroxy-3(2H)-furanone with DNA.  
8 The concentrations used were 10-fold higher than that of spontaneous revertants.  
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Table 2.3: Genotoxicity Data (in vivo) EFSA / FGE.10Rev2 (EFSA, 2011p) 
Only studies relevant for the evaluation of the three candidate aliphatic alpha,beta-unsaturated lactones in the present FGE has been included 
Table 2.3: GENOTOXICITY (In vivo) 
Chemical Name [FL-no:] Test system Test Object Route Dose Result Reference Comments 
(Butyro-1,4-lactone [10.006]) In vivo Bone- marrow 
micronucleus assay 
B6C3F1 mice  Single dose via 
intraperitoneal injection 
80 % of LD50  Negative  (Salamone et al., 1981) Limited relevance because 
PCE/NCE ratio was not 
reported, thus it is not clear if 
the test substance reached the 
bone marrow. 
In vivo Bone- marrow 
micronucleus assay 
CD-1 mice   0.11 - 0.44 ml/kg (110 - 440 
mg/kg)   
Negative  (Tsuchimoto and Matter, 
1981) 
Limited relevance because 
PCE/NCE ratio was not 
reported, thus it is not clear if 
the test substance reached the 
bone marrow. 
In vivo micronucleus assay Mice (B6C3F1/BR hybrid)  80 % of LD50 Negative  (Katz et al., 1981) Limited relevance because 
PCE/NCE ratio was not 
reported, thus it is not clear if 
the test substance reached the 
bone marrow. 
In vivo sperm abnormality Mice (CBA X Balb/c)F1  
 
Daily exposure for five 
days via intraperitoneal 
injection 
0.1 - 1.0 mg/kg bw/day  Negative  (Topham, 1981) Sperm head abnormality test 
does not make use of a genetic 
endpoint. 
In vivo sex- linked recessive 
test 
D. melanogaster  A: via diet 
B: injection 
A: 20000 or 28000 ppm  
B. 15.000 ppm 
Negative  (Foureman et al., 1994) Study in compliance with OECD 
477. 
(Hexano-1,5-lactone  [10.010]) Chromosomal aberration  
in vivo 
 Rat bone-marrow cell  NR  Negative1 (Kawachi et al., 1980b) Summary of results on 186 
compounds. No details on 
methods, concentrations and 
data given, results cannot be 
validated. 
(Undecano-1,4-lactone  [10.002]) In vivo mouse micronucleus 
test 
 2-6 ddY male mice Via intraperitoneal 
injection 
250-2000 mg/kg  Negative  (Hayashi et al., 1988) Single application, only one 
sampling time. Not in 
compliance with current OECD 
474. 
NR: Not reported.  
1)  Presence or absence of metabolic activation not specified.  
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TABLE 3: SUMMARY OF SAFETY EVALUATION  
Table 3: Summary of Safety Evaluation 
Table 3.1: Summary of Safety Evaluation of Three Aliphatic Lactones evaluated by JECFA at their 49th meeting (JECFA, 1998a) 
Table 3.1: Summary of Safety Evaluation of three aliphatic lactones (JECFA, 1998a) 
FL-no 
JECFA-no 
EU Register name Structural formula EU MSDI 1)  
US MSDI 
(μg/capita/day) 
 
Class 2) 
Evaluation procedure 
path 3)  
Outcome on the 
named compound  
[4) or 5)] 
EFSA conclusion on the 
named compound 
(Procedure steps, intake 
estimates, NOAEL, 
genotoxicity) 
 
EFSA conclusion on the 
material of commerce 
10.031 
245 
6-Pentyl-2H-pyran-2-one O O
 
84 
0.1 
Class III 
Not evaluation through the 
Procedure (JECFA) 
 No safety concern at the 
estimated level of intake 
based on the MSDI 
approach. 
No safety concern at the 
estimated level of intake 
based on the MSDI 
approach. 
10.037 
246 
Dec-2-eno-1,5-lactone O O
 
830 
0.1 
Class III 
Not evaluation through the 
Procedure (JECFA) 
 No safety concern at the 
estimated level of intake 
based on the MSDI 
approach. 
No safety concern at the 
estimated level of intake 
based on the MSDI 
approach. 
Racemate (EFFA, 2011c). 
10.044 
438 
Dodec-2-eno-1,5-lactone OO
 
0.12 
8.6 
Class III 
Not evaluation through the 
Procedure (JECFA) 
 No safety concern at the 
estimated level of intake 
based on the MSDI 
approach. 
No safety concern at the 
estimated level of intake 
based on the MSDI 
approach.  
Racemate (EFFA, 2011c). 
1) EU MSDI: Amount added to food as flavour in (kg / year) x 10E9 / (0.1 x population in Europe (= 375 x 10E6) x 0.6 x 365)  =  µg/capita/day. 
2) Thresholds of concern: Class I = 1800 µg/person/day, Class II = 540 µg/person/day, Class III = 90 µg/person/day. 
3) Procedure path A substances can be predicted to be metabolised to innocuous products.  Procedure path B substances cannot. 
4) No safety concern based on intake calculated by the MSDI approach of the named compound. 
5) Data must be available on the substance or closely related substances to perform a safety evaluation. 
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Table 3.2: Summary of Safety Evaluation Applying the Procedure (EFSA / FGE.10Rev2) (EFSA, 2011p) 
Only evaluation summaries relevant for the evaluation of the three candidate aliphatic alpha,beta-unsaturated lactones in the present FGE has been included 
Table 3.2: Summary of Safety Evaluation Applying the Procedure (based on intakes calculated by the MSDI approach) 
FL-no EU Register name Structural formula MSDI 1) 
(μg/capita/day
) 
Class 2) 
Evaluation procedure path 
3) 
Outcome on the 
named compound 
[ 4) or 5] 
Outcome on the 
material of 
commerce [6), 7), 
or 8)] 
Evaluation 
remarks 
10.038 
 
Dec-7-eno-1,4-lactone O O 0.37 
 
Class I 
A3: Intake below threshold 
4) 7)  
10.039 
 
cis-Dec-7-eno-1,4-lactone O O 1.2 
 
Class I 
A3: Intake below threshold 
4) 6)  
10.040 
 
Dec-8-eno-1,5-lactone OO 0.011 
 
Class I 
A3: Intake below threshold 
4) 7)  
10.045 
 
Heptano-1,5-lactone O O 0.012 
 
Class I 
A3: Intake below threshold 
4) 6)  
10.047 
 
Hexadecano-1,16-lactone 
C
CH2
CH2
CH2C
H2
C
H2
H2C
H2C
H2C
H2C
H2C
H2C
H2
C
H2
C
CH2
CH2
O
O
0.024 
 
Class I 
A3: Intake below threshold 
4) 6)  
10.048 
 
Hexadecano-1,4-lactone O O 0.0061 
 
Class I 
A3: Intake below threshold 
4) 6)  
10.049 
 
Hexadecano-1,5-lactone OO 0.024 
 
Class I 
A3: Intake below threshold 
4) 6)  
10.052 
 
3-Methylnonano-1,4-lactone O O 0.61 
 
Class I 
A3: Intake below threshold 
4) 6)  
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Table 3.2: Summary of Safety Evaluation Applying the Procedure (based on intakes calculated by the MSDI approach) 
FL-no EU Register name Structural formula MSDI 1) 
(μg/capita/day
) 
Class 2) 
Evaluation procedure path 
3) 
Outcome on the 
named compound 
[ 4) or 5] 
Outcome on the 
material of 
commerce [6), 7), 
or 8)] 
Evaluation 
remarks 
10.055 
 
Pentano-1,5-lactone O O 0.012 
 
Class I 
A3: Intake below threshold 
4) 6)  
10.058 
 
Tridecano-1,5-lactone OO 0.61 
 
Class I 
A3: Intake below threshold 
4) 6)  
10.059 
 
Hexadec-7-en-1,16-lactone 
O
C O
CH2
CH2
CH2C
H2
C
H2
HC
HC
H2C
H2C
H2C
H2C
H2
C
H2
C
CH2
CH2
Z-isomer shown
1.9 
 
Class I 
A3: Intake below threshold 
4) 7)  
10.063 
 
Hexadec-9-en-1,16 lactone 
O
C O
CH2
CH2
CH2C
H2
C
H2
H2C
H2C
HC
HC
H2C
H2C
H2
C
H2
C
CH2
CH2
Z-isomer shown
48 
 
Class I 
A3: Intake below threshold 
4) 7)  
10.068 
 
Pentadecano-1,14-lactone 
C
CH2
CH2
C
H2
C
H2
H2C
H2C
H2C
H2C
H2C
H2C
H2
C
H2
C
CH
CH3
O
O
0.9 
 
Class I 
A3: Intake below threshold 
4) 6)  
10.168 
 
5,6-Dimethyl-tetrahydro-pyran-
2-one 
OO
1.2 
 
Class I 
A3: Intake below threshold 
4) 6)  
1) EU MSDI: Amount added to food as flavour in (kg / year) x 10E9 / (0.1 x population in Europe (= 375 x 10E6) x 0.6 x 365)  =  µg/capita/day. 
2) Thresholds of concern: Class I = 1800, Class II = 540, Class III = 90 µg/person/day. 
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3) Procedure path A substances can be predicted to be metabolised to innocuous products.  Procedure path B substances cannot. 
4) No safety concern based on intake calculated by the MSDI approach of the named compound. 
5) Data must be available on the substance or closely related substances to perform a safety evaluation. 
6) No safety concern at estimated level of intake of the material of commerce meeting the specification of Table 1 (based on intake calculated by the MSDI approach). 
7) Tentatively regarded as presenting no safety concern (based on intake calculated by the MSDI approach) pending further information on the purity of the material of commerce and/or information on stereoisomerism. 
8) No conclusion can be drawn due to lack of information on the purity of the material of commerce. 
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ABBREVIATIONS 
CAS  Chemical Abstract Service 
CEF  Panel on Food Contact Materials, Enzymes, Flavourings and Processing Aids 
CHO  Chinese hamster ovary (cells) 
CoE  Council of Europe 
DNA  Deoxyribonucleic acid 
EFSA  The European Food Safety Authority 
EPA  United States Environmental Protection Agency 
ER  Endoplasmatic reticulum  
EU  European Union 
FAO  Food and Agriculture Organization of the United Nations  
FEMA  Flavor and Extract Manufacturers Association 
FGE  Flavouring Group Evaluation  
FLAVIS (FL) Flavour Information System (database) 
G.I.  Gastrointestinal  
GLP  Good laboratory practise 
ID  Identity 
Ip  Intraperitoneal 
IR  Infrared spectroscopy 
JECFA  The Joint FAO/WHO Expert Committee on Food Additives 
MSDI  Maximised Survey-derived Daily Intake 
mTAMDI Modified Theoretical Added Maximum Daily Intake 
NCE  Normochromatic erythrocyte 
No  Number 
NOAEL No observed adverse effect level 
NTP  National Toxicology Program 
PCE  Polychromatic erythrocyte 
SCE  Sister chromatic exchange 
SCF  Scientific Committee on Food 
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WHO  World Health Organisation 
